Aims: Resting heart rate (HR ate ) is a modifiable risk factor among patients with cardiovascular disease, including aortic stenosis (AS). However, the effect of resting HR ate on clinical outcomes of patients with severe symptomatic AS undergoing transcatheter aortic valve implantation (TAVI) is unknown. Our aim was therefore to assess the effect of resting HR ate on clinical outcomes among high-risk patients with symptomatic severe AS in normal sinus rhythm (NSR) undergoing TAVI.
Introduction
A high resting heart rate (HR ate ) is a potentially modifiable cardiovascular risk factor, both in the general population and among patients with cardiovascular disease [1] [2] [3] . Large observational studies have shown a link between increased HR ate and all-cause mortality and cardiovascular events in patients with coronary artery disease, hypertension, metabolic syndrome and heart failure [4] [5] [6] [7] . A high resting HR ate has recently been shown to be associated with major cardiovascular events and cardiovascular death among patients with asymptomatic aortic stenosis (AS) 8 . In addition, it was recently demonstrated that sympathetic nervous system (SNS) activity is increased and arterial baroreflex is impaired in patients with AS undergoing transcatheter aortic valve implantation (TAVI) 9 . A high HR ate reflects an increase in SNS activity, which may trigger or exacerbate many of the pathophysiological features associated with AS, such as cardiac hypertrophy and decreased peripheral perfusion 9 . While there have been several studies published to date assessing the effect of rhythm disturbances (e.g., atrial fibrillation 10, 11 ) and conduction abnormalities (e.g., left bundle branch block 12, 13 ) on clinical outcomes after TAVI, the majority of patients remain in normal sinus rhythm after TAVI 10, 11 . Heart rate is an easily modifiable risk factor and therefore it is clinically useful to determine whether or not an elevated heart rate may affect clinical outcomes after TAVI. However, to the best of our knowledge, this association has never before been investigated. We therefore aimed to assess the effect of resting HR ate on clinical outcomes among high-risk patients with symptomatic severe AS in normal sinus rhythm undergoing TAVI.
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Methods
PATIENT POPULATION
This is a retrospective analysis of prospectively collected data from a database that includes all patients with severe native valve AS who underwent TAVI at our institution between August 2007 and December 2012 (n=606). All patients were deemed inoperable or at high surgical risk for conventional surgery by a multidisciplinary team comprising interventional cardiologists and cardiovascular surgeons. Patient flow is shown in Figure 1 . Included in this study were all consecutive patients with symptomatic severe native valve AS in sinus rhythm on 12-lead electrocardiogram (ECG) performed ≤30 days prior to TAVI. Exclusion criteria are shown in Figure 1 . Patients were dichotomised into low (<77 beats per minute [bpm] ) and high (≥77 bpm) HR ate groups according to the baseline HR ate measured on the pre-procedural 12-lead ECG. Discharge 12-lead ECGs were subsequently analysed after TAVI to assess the discharge HR ate and any changes in HR ate occurring after TAVI. A cut-off HR ate of 77 bpm was chosen based on the results of the randomised Systolic Heart failure treatment with the I f inhibitor ivabradine Trial (SHIFT), where evidence of a significant treatment effect with ivabradine was noted only in the subgroup of patients with baseline heart rates higher than the median 77 bpm 14 . The cohort study complies with the Declaration of Helsinki, was approved by the local ethics committee, and all patients provided written informed consent.
ELECTROCARDIOGRAPHY AND ECHOCARDIOGRAPHY
Available 12-lead ECGs were analysed individually by two cardiologists unaware of clinical data. Discrepancies were resolved through consensus. Transthoracic echocardiography was performed in all included patients at baseline as previously described 15 .
CARDIAC CATHETERISATION
All TAVI patients underwent coronary angiography and 290/349 (83%) had a full invasive evaluation by right and left heart catheterisation prior to TAVI as previously described 16 .
TRANSCATHETER AORTIC VALVE IMPLANTATION PROCEDURE
TAVI was performed as previously described. Vascular access was transfemoral using the Medtronic CoreValve Revalving System (MCRS) (Medtronic, Minneapolis, MN, USA), Edwards SAPIEN/XT (ESV) (Edwards Lifesciences, Irvine, CA, USA) or transapical for the latter bioprosthesis or the self-expanding Symetis ACURATE TA™ valve (SA) (Symetis Inc., Ecublens, Switzerland) or trans-subclavian using the MCRS 16 .
CLINICAL FOLLOW-UP
Adverse events were assessed in hospital, and regular clinical follow-up was performed at one, six, 12 and 24 months by means of a clinical visit or standardised telephone interview. All suspected events were adjudicated by an unblinded clinical events committee, comprising cardiac surgeons and interventional cardiologists who were unaware of the heart rate assessments.
STUDY ENDPOINTS
Clinical endpoints were defined according to the criteria proposed by the Valve Academic Research Consortium-2 (VARC-2) consensus document 17 . The primary endpoint was all-cause mortality at two years. The secondary endpoint was cardiovascular death at two years. All endpoints were assessed for both baseline and discharge HR ate . 
STATISTICS
Results
BASELINE CHARACTERISTICS
Patient characteristics are shown in Table 1 . The present analysis included 349 patients out of 606 consecutive patients (58%) undergoing TAVI between August 2007 and December 2012 in our institution. Of the 349 included patients in sinus rhythm prior to TAVI, 219 (63%) had a low resting HR ate (LHR) (defined as <77 bpm) and 130 (37%) had a high resting HR ate (HHR) (defined as ≥77 bpm) at baseline before TAVI. As compared with LHR, patients with HHR were significantly younger, more likely to be female, less likely to have undergone previous cardiac surgery and previous percutaneous coronary intervention, and were less likely to be taking beta-blockers. ECGs were performed at a mean±standard deviation of 3.6±5.0 days (range 0-28 days) prior to TAVI. Data on periprocedural changes in medications, including beta-blockers and calcium channel blockers, are shown in Table 1 . We found no significant difference in the prevalence of beta-blockers (56% vs. 57%, p=0.90) or calcium channel blockers (27% vs. 21%, p=0.31) prescribed at discharge between low and high heart rate patients.
ELECTROCARDIOGRAPHIC, ECHOCARDIOGRAPHIC AND INVASIVE HAEMODYNAMIC CHARACTERISTICS
Baseline electrocardiographic, echocardiographic and invasive haemodynamic characteristics are shown in Table 2 . As compared with LHR, patients with HHR had smaller aortic valve areas, worse LV systolic and diastolic function and a higher prevalence of moderate to severe mitral regurgitation on baseline echocardiography. Patients with HHR also had a more adverse baseline haemodynamic profile on pre-procedural right and left heart catheterisation. Interestingly, despite significantly lower stroke volume indices among HHR patients, no significant differences in cardiac indices were observed between groups. No significant differences in pulmonary artery systolic pressures were observed between groups. As expected, HR ate measured during right heart catheterisation was significantly higher among HHR patients as compared with LHR patients, thereby corroborating the HR ate measured on baseline ECG.
PROCEDURAL CHARACTERISTICS
Procedural characteristics are shown in Table 3 . The majority of patients included in the present analysis underwent transfemoral TAVI (79%). No significant differences in procedural characteristics were found between groups.
CLINICAL OUTCOMES STRATIFIED ACCORDING TO BASELINE HR ate
Clinical follow-up was complete for 338/349 (97%) patients (n=9 lost to follow-up and n=2 refused follow-up). Event rates with adjusted hazard ratios (adj HR) and 30-day landmark analyses for all-cause mortality and cardiovascular death at two years stratified according to baseline HR ate are provided in Table 4 . Time-to-event curves for all-cause mortality and cardiovascular death at two-year follow-up are shown in Figure 2A and Figure 2B , respectively. A 30-day landmark analysis for all-cause mortality and cardiovascular death at two years is shown in Figure 2C and Figure 2D , respectively. As compared with baseline LHR, no significant differences in all-cause mortality or cardiovascular death were observed among patients with baseline HHR at two-year follow-up. On 30-day landmark analysis, no significant differences in all-cause mortality or cardiovascular death were observed among patients with baseline HHR on unadjusted or adjusted analysis at two-year follow-up (Table 4 , Figure 2C , Figure 2D ). No significant interaction was observed between overall mortality (p-interaction 0.91) and cardiovascular death (p-interaction 0.44) event rates occurring before and after 30-day follow-up ( Figure 2C, Figure 2D ).
CHANGES IN HR ate AFTER TAVI
Changes in resting HR ate measured on 12-lead ECGs before and after TAVI among patients remaining in normal sinus rhythm on discharge ECG (n=197) are shown in Table 5 and Figure 3 . Overall, the mean HR ate increased after TAVI on discharge ECG. Among LHR patients, the mean HR ate significantly increased following TAVI on discharge as compared with baseline ECG. Conversely, 
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Figure 2. Clinical outcomes according to baseline heart rate. Kaplan-Meier analysis of death (A) and cardiovascular death (B) at two years among patients undergoing transcatheter aortic valve implantation (TAVI) stratified according to low (heart rate <77 beats per minute [bpm]) versus high (heart rate ≥77 bpm) baseline resting heart rate. Thirty-day landmark analysis of death (C) and cardiovascular death (D) at two years among patients undergoing TAVI stratified according to low versus high resting heart rate at baseline.
among HHR patients, the mean HR ate significantly decreased after TAVI on discharge as compared with baseline ECG.
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Figure 3. Scatter plot showing the changes in heart rate before and after transcatheter aortic valve implantation (TAVI) among patients remaining in normal sinus rhythm as measured on the baseline and discharge 12-lead electrocardiograms (n=197 patients), respectively.
The resting heart rate at baseline on the x-axis is plotted against the change in heart rate (delta heart rate) after TAVI, i.e., discharge heart rate minus baseline heart rate, on the y-axis. according to discharge HR ate are provided in Table 6 . Time-toevent curves for all-cause mortality and cardiovascular death at two-year follow-up stratified according to discharge HR ate are shown in Figure 4A and Figure 4B , respectively. A landmark analysis at 30 days for all-cause mortality and cardiovascular death at two years is shown in Figure 4C and Figure 4D , respectively. As compared with discharge LHR, no significant differences in all-cause mortality or cardiovascular mortality among discharge HHR patients were observed. On 30-day landmark analysis, discharge HHR was significantly associated with all-cause mortality at two-year follow-up (HR 2.30, 95% CI: 1.16-4.56, p=0.017) although this significance was lost after extensive adjustment for comorbidities (adj HR 2.01, 95% CI: 0.98-4.09, p=0.056). A statistically significant interaction was observed for overall mortality (p-interaction 0.021) and cardiovascular death (p-interaction 0.031) events occurring before and after 30-day follow-up ( Figure  4C, Figure 4D ) for discharge HR ate .
Discussion
The main finding from the present study was that neither baseline nor discharge HHR was associated with overall or cardiovascular mortality two years after TAVI. Although patients with HHR had worse echocardiographic and invasive haemodynamic profiles at baseline as compared with LHR patients, this did not translate into worse clinical outcomes at two-year follow-up. A novel observation was that TAVI resulted in a significant physiological modification of the resting HR ate , i.e., the majority of LHR patients had a significant increase in resting HR ate , whereas the majority of HHR patients exhibited a significant decrease in resting HR ate Table 6 . Adjusted clinical outcomes at 2-year follow-up stratified by discharge resting heart rate (normal sinus rhythm).
Discharge heart rate <77 vs ≥77 p-value <77 bpm n=100 ≥77 bpm n=97 HR (95% CI) Depicted are number of events (incidence rates from life tables, %). Inverse probability of treatment weighted (IPTW) hazard ratios (HR [95% confidence intervals]) from Cox regressions. IPTW for high versus low heart rate calculated using the following baseline clinical variables: age, gender, height, body mass index, diabetes mellitus, coronary artery disease, multivessel disease, previous myocardial infarction, cardiac surgery, percutaneous coronary intervention, peripheral vascular disease, chronic obstructive pulmonary disease (COPD), renal failure, moderate or severe mitral regurgitation, New York Heart Association (NYHA) functional Class III or IV (selected if p<0.2 on all-cause death at two years or p<0.2 on high versus low). Missing data replaced with single imputation (COPD, NYHA II or IV, mitral regurgitation).
after TAVI (Figure 3) . The latter observation may explain the lack of effect of baseline resting HR ate on clinical outcomes after TAVI. In contrast to baseline HR ate , a discharge HHR was significantly associated with overall mortality two years after TAVI on 30-day landmark analysis, although this significance was lost after extensive adjustment (HR 2.01, 95% CI: 0.98-4.09, p=0.056).
RELATIONSHIP BETWEEN RESTING HR ate AND OUTCOMES IN CARDIOVASCULAR DISEASE
A significant association between resting HR ate and mortality has been reported among patients with a variety of cardiovascular diseases, including acute coronary syndromes 18 , and hypertension 19 . Furthermore, HR ate was found to be directly related to the risk of death, cardiovascular death, or admission to hospital in patients with heart failure 20 , and HR ate reduction was found to be associated with improved outcomes 21 . Resting HR ate is included in several risk assessment algorithms for patients after acute coronary syndromes, such as the Global Registry of Acute Coronary Events risk prediction (GRACE) score and the Thrombolysis In Myocardial Infarction (TIMI) risk score 22, 23 . Ivabradine is a selective inhibitor of the funny current (I f ), which results in HR ate reduction with no other apparent direct cardiovascular effects 24 . In the Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL) trial, ivabradine-induced HR ate reduction did not affect the primary composite endpoint of cardiovascular death, hospital admission for acute myocardial infarction, and hospital admission for new-onset or worsening heart failure 24 . However, it did reduce the secondary endpoints of hospital admission for fatal and non-fatal myocardial infarction and coronary revascularisation. Furthermore, a subanalysis of the BEAUTIFUL trial revealed that an HR ate of ≥70 bpm was associated with a 34% increased risk of cardiovascular death, a 53% increase in admission to hospital for heart failure, and a 46% increase for admission to hospital for myocardial infarction compared with HR ate lower than 70 bpm, even after adjustment for other predictors of outcomes 7 . In the Systolic Heart failure treatment with the I f inhibitor ivabradine Trial (SHIFT), comprising patients in sinus rhythm with a resting HR ate ≥70 bpm (in contrast to the 60 bpm cut-off used in the BEAUTIFUL trial) and LVEF ≤35%, ivabradine was associated with an 18% relative risk reduction in the composite primary endpoint of cardiovascular death or hospital admission for worsening heart failure (p<0.0001) 14 . p =0.12
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High discharge heart rate (≥77 bpm) Low discharge heart rate (<77 bpm) The investigators directly measured muscle sympathetic nerve activity and arterial baroreflex gain in 14 patients with severe symptomatic AS before and a week after TAVI and in 14 control patients without AS 9 . They found that patients with AS had increased SNS activity associated with a decrease in sympathetic arterial baroreflex gain compared with controls, and that TAVI normalised these parameters 9 . In the present study, the normalisation of sympathetic overactivity may explain the significant HR ate reduction observed among HHR patients after TAVI. This may ultimately explain the lack of differences in clinical outcomes observed between patients with HHR and LHR after TAVI. We observed that HHR patients had significantly lower stroke volumes and stroke volume indices on right heart catheterisation as compared with LHR patients. It is likely that this low flow state leads to activation of the SNS leading to an increase in HR ate in an effort to compensate for the low stroke volume. We also observed that patients with LHR had a significant increase in HR ate after TAVI. The reason for this is unclear. Further studies correlating changes in heart rate after TAVI with post-procedural changes in cardiac output and stroke volume are required in order to explain this phenomenon.
Limitations
There are a number of limitations that need to be considered when interpreting this study. First, the present study was a single-centre retrospective study. Even though all data were prospectively collected and all events adjudicated by an independent clinical events committee, our results may contain unmeasured bias. Second, the sample size is relatively small (n=349), and only 197 patients had available data for discharge analysis. However, to the best of our knowledge, this is the first study to question the association between resting sinus rhythm HR ate and clinical outcomes in TAVI patients. Third, this is not a consecutive patient series, as patients with missing ECGs or those who received ECGs >30 days prior to TAVI were excluded. Furthermore, not all included patients had discharge ECGs available. Finally, there are other factors that can influence resting HR ate apart from SNS activity.
Conclusions
Neither baseline nor discharge resting HHR was associated with all-cause mortality or cardiovascular death after TAVI.
Impact on daily practice
Resting sinus rhythm heart rate is known to be a modifiable risk factor for cardiovascular disease, including aortic stenosis. However, there have been no studies to date assessing the effect of baseline and discharge resting sinus rhythm heart rate on clinical outcomes after transcatheter aortic valve implantation (TAVI). We observed that resting sinus rhythm heart rate at baseline and discharge had no effect on two-year mortality rates after TAVI.
